Crude and adjusted NMOSD prevalence estimates by region, ancestry and overall
| Subpopulation | NMOSD cases | Population | Latitude | Crude prevalence† | Adj prevalence‡ | |||
| Clinical only | Clinical and laboratory | Laboratory only* | Total | (° South) | (per 100 000) | (per 100 000) | ||
| Region | ||||||||
| QLD/NT | 2 | 12 | 26 (2) | 40 | 4 898 100 | 25.0954 | 0.82 (0.56 to 1.08) | 0.95 (0.78 to 1.12) |
| WA | 1 | 1 | 4 | 6 | 2 517 200 | 31.5906 | 0.24 (0.05 to 0.43) | 0.40 (0.00 to 0.89) |
| NSW/ACT | 11 | 17 | 27 (2) | 55 | 7 791 100 | 33.5302 | 0.68 (0.50 to 0.86) | 0.93 (0.71 to 1.15) |
| SA | 2 | 3 | 2 | 7 | 1 670 800 | 34.8474 | 0.37 (0.09 to 0.64) | 0.44 (0.24 to 0.63) |
| VIC/TAS | 3 | 10 | 13 (2) | 26 | 6 250 600 | 38.0848 | 0.43 (0.24 to 0.62) | 0.56 (0.42 to 0.71) |
| NZ | 6 | 9 | 6 (2) | 21 | 4 442 100 | 38.1507 | 0.38 (0.23 to 0.53) | 0.47 (0.37 to 0.58) |
| Ancestry | ||||||||
| Asian | 6 | 12 | 22 | 40 | 3 259 047 | 1.23 (0.85 to 1.61) | 1.57 (1.15 to 1.98) | |
| Other | 18 | 41 | 56 (8) | 115 | 24 410 853 | 0.44 (0.36 to 0.52) | 0.57 (0.50 to 0.65) | |
| Total | 25 | 52 | 78 | 155 | 27 669 900 | 0.65 (0.58 to 0.73) | 0.70 (0.61 to 0.78) | |
*Figures in parentheses indicate estimated numbers of missed seronegative cases added to the estimate.
†Excludes estimated numbers of missed seronegative cases, figures in parentheses indicate 95% CI.
‡Adjusted using Lincoln-Peterson capture–recapture methodology, figures in parentheses indicate 95% CI.
ACT, Australian Capital Territory; Adj, adjusted; NMOSD, neuromyelitis optica spectrum disorder; NSW, New South Wales; NT, Northern Territory; NZ, New Zealand; QLD, Queensland; SA, South Australia; TAS, Tasmania; VIC, Victoria; WA, Western Australia.